Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company whose news flow reflects its role in life science tools, bioactive reagents, diagnostics, and spatial biology. Company announcements frequently highlight financial results, product launches, collaborations, and participation in healthcare and investor conferences, giving investors and researchers insight into how Bio-Techne is executing its strategy.
Recent press releases include quarterly and annual financial updates, where Bio-Techne reports net sales, segment performance for its Protein Sciences and Diagnostics and Spatial Biology segments, and commentary on market conditions. These earnings communications often discuss organic revenue trends, operating margins, and portfolio decisions such as divestitures of non-core businesses.
Product and technology news from Bio-Techne covers launches of analytical instruments, spatial biology assays, and multiomic workflows. Examples include announcements of next-generation protein analysis systems with multiplexing capabilities, spatial biology platforms that combine RNA and protein detection, and assays that visualize protein-protein interactions within tissue at subcellular resolution. Such updates show how the company is expanding its proteomic analytical tools and spatial biology offerings, which it identifies as growth pillars.
Bio-Techne also issues news about strategic collaborations and licensing agreements. Recent items describe partnerships in AI-enabled protein design, multiomic spatial analysis with academic and industry partners, and initiatives supporting cell and gene therapy manufacturing workflows. In addition, the company regularly announces its participation in major healthcare and investor conferences, where management presents its outlook and strategy.
This TECH news page aggregates these types of updates so readers can follow Bio-Techne’s financial reporting, product innovation, strategic partnerships, and conference activity in one place. Investors, analysts, and scientists can use this feed to monitor developments across the company’s life science tools, diagnostics, and spatial biology businesses.
Summary not available.
Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) have announced a collaboration to develop a comprehensive protein characterization solution. This integration will combine Bio-Techne's Maurice icIEF separation instrument with 908 Devices' ZipChip device. The partnership aims to streamline workflow for scientists, enhancing drug development efficiency via in-depth analysis of biotherapeutics. The combination of these technologies is expected to deliver faster commercialization, leveraging high-resolution separation techniques and mass spectrometry capabilities.
908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ: TECH) announced a collaboration to enhance protein characterization workflows. This partnership combines Bio-Techne's Maurice icIEF separation instrument with 908 Devices' ZipChip technology, streamlining the analysis process for biotherapeutics. The integrated solution aims to improve drug development efficiency by providing rapid, high-resolution separation techniques and mass spectrometry identification, catering to the growing biopharmaceutical market.
Bio-Techne Corporation (NASDAQ:TECH) announced the launch of DNAscope Assays, expanding their Advanced Cell Diagnostics RNAscope technology. This new chromogenic DNA in situ hybridization (ISH) technology allows for single-cell resolution to visualize DNA aberrations in FFPE tissues using standard bright-field microscopes. DNAscope provides advantages over traditional FISH techniques, offering precise detection of small genomic regions. Kim Kelderman, President of Diagnostics and Genomics Segment, stated that this launch strengthens their position in spatial genomic analysis, enhancing multi-omic capabilities for faster decision-making.
Bio-Techne Corporation (NASDAQ: TECH) announced the rebranding of its Pharma Assay Services to Professional Assay Services, aimed at enhancing accessibility for global academic and clinical institutions. The updated services include in situ hybridization (ISH) gene expression analysis, tissue procurement, and custom assay development. Supported by a team of experts, these services comply with Good Clinical Laboratory Practices (GCLP). Kim Kelderman, President of Diagnostics and Genomics, emphasized the commitment to facilitate faster drug development timelines while maintaining cost efficiency.
Bio-Techne Corporation (NASDAQ: TECH) has entered a licensing agreement with Xencor, Inc. for the use of its proprietary antibody in developing innovative cancer therapeutics. This marks Bio-Techne's third collaboration with Xencor, emphasizing their role in the immuno-oncology field. The agreement allows Xencor to utilize Bio-Techne's extensive antibody portfolio alongside its XmAb® protein engineering technology, aimed at creating bispecific antibodies and engineered cytokines. Bio-Techne's commitment to the biopharma industry continues to grow through these strategic partnerships.
Bio-Techne Corporation (NASDAQ:TECH) has launched Abby, an advanced chemiluminescence system designed to automate the traditional Western blotting process. Abby features picogram-level sensitivity and the innovative RePlex™ technology, enabling sequential immunoassays. Additionally, the new Compass software enhances data analysis efficiency. The company also announced the upcoming Stellar™ NIR and IR modules for Jess™, which aim to elevate fluorescence Western blotting sensitivity. Bio-Techne emphasizes that these products contribute to faster, more reproducible results, essential for modern research environments.
Bio-Techne Corporation (NASDAQ: TECH) announced the completion of its acquisition of Asuragen, Inc., valued at $215 million in cash with up to $105 million contingent on future milestones. This acquisition enhances Bio-Techne's portfolio with advanced molecular diagnostic products, including genetic screening and oncology testing kits. It also provides a GMP-compliant manufacturing facility and a CLIA-certified laboratory. The company anticipates significant growth synergies from this deal, particularly in commercializing molecular products for broader market adoption.
Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on May 6, 2021, at 8:00 a.m. CDT to discuss its third quarter 2021 financial results. Interested participants can join by dialing 1-877-407-9208 or accessing the webcast at public.viavid.com. A recorded replay will be available from 11:00 a.m. CDT on May 6 until 11:00 p.m. CDT on June 6, 2021. In fiscal 2020, Bio-Techne generated approximately $739 million in net sales.
Bio-Techne Corporation (NASDAQ: TECH) announces the launch of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an innovative extracellular matrix hydrogel aimed at enhancing organoid and pluripotent stem cell cultures. This product features increased total protein content, optimized protein composition, and improved tensile strength, while also reducing reliance on growth factors. Dave Eansor, President of Protein Sciences Segment, emphasizes its importance for drug discovery and regenerative medicine, addressing a critical market need.
FAQ
What is the current stock price of Bio-Techne (TECH)?
What is the market cap of Bio-Techne (TECH)?
